Corcept Therapeutics Inc. (CORT) reported a fourth-quarter net loss of $9.9 million, or $0.12 per share, compared to a net loss of $7.1 million, or $0.10 per share, for the fourth quarter of 2010.
Research and development expenses increased to $6.6 million, from $4.7 million in the year ago quarter.
During the comparable periods, research and development expenses increased primarily due to higher costs associated with the submission and prosecution of our NDA for Korlym, purchase of Korlym's active pharmaceutical ingredient, manufacture of Korlym tablets and manufacturing development activities.
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org